- |
My Account- |
United States (Change Country)You can order by phone, email or fax Tel: +1-832-582-8158 Fax: +1-713-796-9816 Email: [email protected] |
| Formulation: | A collection of 84 chemotherapeutic agents supplied as lyophilized powder or pre-dissolved DMSO solutions. | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Container: | A: Deep-well 96-well Plate (Free of Charge) B: 96-well racks with TrakMate screwtop tubes & caps ($ 100/Set) |
||||||||||||
| Stability: |
|
||||||||||||
| Shipping: | Blue ice | ||||||||||||
| Packaging: | Inert gas |
If you need to download the Chemotherapeutic Agent Library Contents (.xlsx and .sdf), please contact us via [email protected]
| Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Capecitabine for 48h. Cell survival was measured by a standarad MTT assay. |
Data from [Nature 2010.November;468:973-977]
AZD6244 (Selumetinib) purchased from Selleck
Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Capecitabine for 48h. Cell survival was measured by a standarad MTT assay.
| A. MCF10A-Ras overexpressing a vector control or the gene of interest (GeneX), or MCF7 expressing a scramble or a siRNA for the geneX were treated with DMSO or with Carboplatin for 24h. Resistant colonies were allowed to grow for 2 weeks, and are then stained with Crystal Violet. B. Quantification of the results. |
Data independently produced by Dr Helen Sadik of Johns Hopkins University
Carboplatin purchased from Selleck
A. MCF10A-Ras overexpressing a vector control or the gene of interest (GeneX), or MCF7 expressing a scramble or a siRNA for the geneX were treated with DMSO or with Carboplatin for 24h. Resistant colonies were allowed to grow for 2 weeks, and are then stained with Crystal Violet. B. Quantification of the results.
| A. Viability curve for the c-Kit mutant MelMS melanoma cell line treated with increasing concentrations of imatinib for 72h (relative to DMSO-treated controls; mean ± sd; n=3) B. MelMS melanoma cells were treated with 50nM imatinib for 24h. The effects on c-Kit, ERK and AKT activation were determined by immunoblotting. |
Data independently produced by Dr Helen Rizos from the university of Sydney
Imatinib Mesylate purchased from Selleck
A. Viability curve for the c-Kit mutant MelMS melanoma cell line treated with increasing concentrations of imatinib for 72h (relative to DMSO-treated controls; mean ± sd; n=3) B. MelMS melanoma cells were treated with 50nM imatinib for 24h. The effects on c-Kit, ERK and AKT activation were determined by immunoblotting.
| Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay. |
Data independently produced by Dr Helen Sadik of Johns Hopkins University
Gemcitabine Hydrochloride (Gemzar) purchased from Selleck
Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Gemcitabine for 48h. Cell survival was measured by a standarad MTT assay.
| Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 mM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ± SD. |
Data from [Cancer Cell 2011.June;19:1–13]
Rapamycin(Sirolimus) purchased from Selleck
Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 mM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ± SD.
| Sunitinib limits the colonial growth of HT-29 by downregulating HIF-1a. (A) The number and size of colonies formed in soft agar. The numbers of small colonies (<50 lm diameter) were not different among conditions of a serial concentration of sunitinib. On the contrary, large colonies (>50 lm diameter) disappeared after incubation with sunitinib. Each point represents the mean and SD from four separate experiments. (B) HIF-1a expression and hypoxia within HT-29 colony. After colonies grew for 4 weeks, HIF-1a and hypoxia were visualized by immunofluoroscence staining. Bar = 20 lm. |
Data from [Biochem Bioph Res Co 2010 June;398:205–211]
Sunitinib Malate (Sutent) purchased from Selleck
Sunitinib limits the colonial growth of HT-29 by downregulating HIF-1a. (A) The number and size of colonies formed in soft agar. The numbers of small colonies (<50 lm diameter) were not different among conditions of a serial concentration of sunitinib. On the contrary, large colonies (>50 lm diameter) disappeared after incubation with sunitinib. Each point represents the mean and SD from four separate experiments. (B) HIF-1a expression and hypoxia within HT-29 colony. After colonies grew for 4 weeks, HIF-1a and hypoxia were visualized by immunofluoroscence staining. Bar = 20 lm.
A collection of 729 inhibitors
A collection of 1484 bioactive compounds
A collection of 118 tyrosine kinase inhibitors
A collection of 277 kinase inhibitors
A collection of 789 FDA approved drugs
A collection of 146 natural products
